01246 BOILLHEALTHCARE
- 0.305
- +0.061+25.00%
BOILLHEALTHCARE News
Baoji Health (01246): Yuen Wai-keung appointed as company secretary
Baoji Health (01246) issued an announcement. Chen ?$#@$ has resigned as the company's company secretary; authorized representative; and legal process agent...
Boill Healthcare Auditor Resigns; Replacement Named
Boill Healthcare Holdings (HKG:1246) said BDO resigned as its auditor after a disagreement over the audit fee for the year ended March 31, 2024, according to a Tuesday Hong Kong filing. The company ap
Baoji Health (01246) appoints Zhibao Xinqin as new auditor
Baoji Health (01246) issued an announcement. Hong Kong Lixin Dehao Certified Public Accountants Co., Ltd. has resigned as the company's auditor since...
Boill Healthcare's CEO Steps Down
Boill Healthcare Holdings (HKG:1246) said Qiu Bin has tendered his resignation as an executive director and the chief executive officer (CEO) of the firm effective today, March. 8, according to a Frid
Baoji Health (01246.HK): Qiu Bin resigns as executive director
Gelonghui March 8 | Baoji Health (01246.HK) announced that Mr. Qiu Bin has resigned as the company's executive director and chief executive with effect from March 8, 2024.
Baoji Health (01246.HK) appoints Tang Man-yee as independent non-executive director
Gelonghui, January 26, 丨 Baoji Health (01246.HK) announced (i) the resignation of Mr. Chen Zhiqiang as an independent non-executive director; and (ii) the appointment of Ms Tang Man-yee as an independent non-executive director, all with effect from January 27, 2024.
Baoji Health (01246.HK) appoints Chen ?$#@$ as company secretary
Gelonghui, January 5 | Baoji Health (01246.HK) announced that Mr. Wu Jianming has resigned as (i) company secretary and (ii) authorized representative of the Company. After Mr. Ng's resignation, Ms. Chan Sze Ting was appointed as company secretary, authorized representative, and corporate legal proceeding agent representing the company under Part 16 of the Companies Ordinance, Chapter 622 of the Hong Kong Laws, to receive legal process documents and notices in Hong Kong, effective January 5, 2024.
Boill Healthcare Sells Stake in Subsidiary for HK$29.5 Million
Boill Healthcare Holdings (HKG:1246) sold the 51% holdings it owned in British Virgin Islands-incorporated subsidiary Pearl Swirls for a consideration of HK$29.5 million. Excellent Speed bought the st
Baoji Health (01246.HK) plans to sell 51% of Zhenxuan's shares for HK$29.46 million
Gelonghui, December 29, 丨 Baoji Health (01246.HK) announced that on December 29, 2023, the company and the buyer agreed to sell the target shares and the buyer agreed to buy the target shares, which is equivalent to 51% of the issued share capital of the target company Zhenxuan Co., Ltd., at a cost of HK$29.46 million. The Hong Kong subsidiary is a limited company incorporated in Hong Kong. It mainly engages in foundation business in Hong Kong as a foundation subcontractor. A Hong Kong subsidiary is a direct wholly-owned subsidiary of the target company. Prior to completion, the target company held 51% of the company's interests and the buyer held 49% of the rights
BOILLHEALTHCARE: 2023 Interim Report
Boill Healthcare Holdings' Attributable Loss Narrows
Boill Healthcare Holdings' (HKG:1246) attributable loss narrowed to HK$8 million in the first fiscal half from HK$96 million in the year-ago period, a Friday filing said. Loss from continuing operatio
Baoji Health (01246) released interim results. Shareholders accounted for a loss of HK$7.988 million, a year-on-year narrowing of 91.68%
Baoji Health (01246) announced interim results for the six months ended September 30, 2023, and continued operating income...
BOILLHEALTHCARE: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2023
Baoji Health (01246.HK) plans to hold a board meeting on November 24 to approve the interim results
Gelonghui November 14 | Baoji Health (01246.HK) announced that the company will hold a board meeting on November 24, 2023 (Friday) to consider and approve (including) the interim results of the company and its subsidiaries for the six months ended September 30, 2023, and consider paying interim dividends (if any).
Boill Healthcare Settles $39.5 Million Loan Facility
Boill Healthcare Holdings (HKG:1246) settled a loan facility worth $39.5 million in full, the company said in a Friday disclosure. As a result of the settlement, the pledged shares representing 52.3%
BOILLHEALTHCARE: Annual Report 2023
Preservation Health (01246) released annual results. Shareholders' losses of HK$428 million decreased 17.29% year-on-year
According to Zhitong Finance App News, Baoji Health (01246) announced the results for the year ended March 31, 2023. The group achieved revenue of HK$348 million, a decrease of 65.33% over the previous year; loss due to company owners was HK$428 million, a decrease of 17.29% over the previous year; and continued operations lost HK$16.47 cents per share. The announcement stated that the decrease in revenue was mainly due to a decrease in properties delivered under the Yangzhong Project in FY2023.
Preserving Health (01246.HK): Net loss of HK$528 million in FY2023
On June 28, GLONGHUI | Baoji Health (01246.HK) announced that in FY2023, the Group's revenue from continuing operations was approximately HK$348.3 million, a decrease of about 65.3% over the previous year. The decrease in earnings was mainly due to fewer properties delivered under the Yangzhong Project in FY2023. In FY2023, the Group's net loss was approximately HK$527.6 million, a decrease of approximately HK$228.1 million from approximately HK$755.7 million in FY2022. The Group's overall poor performance in FY2023 was due to the fact that the Group had terminated operations and recorded losses, as well as the adverse effects and industry links due to the pandemic
BOILLHEALTHCARE: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 MARCH 2023
Baoji Health (01246.HK) will hold a board meeting on June 28 to approve annual results
Glonghui, June 15 丨 Baoji Health (01246.HK) announced that the company will hold a board meeting on June 28, 2023 to consider and approve the annual results of the company and its subsidiaries for the year ending March 31, 2023, and to consider the payment of a final dividend (if any).
Analysis
Price Target
No Data
